OXOLIFE has published the results of a Phase I clinical trial in the International Journal of Fertility & Sterility, evaluating the safety, tolerability, and pharmacokinetics of the compound OXO-001 in healthy women of childbearing age. The randomized, double-blind, placebo-controlled study included 30 volunteers. Results showed that OXO-001 was well-tolerated, with no serious adverse events or negative effects on ovarian or endometrial function. These findings support the compound’s safety and pave the way for further clinical research phases. https://www.ijfs.ir/article_714642.html